COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Appili Therapeutics Inc.
An independent Data and Safety Monitoring Board (DSMB) recommended Appili's ongoing Phase 3 PRESECO (PREventing SEvere COVID-19) study evaluating favipiravir for the treatment of patients with mild-to-moderate COVID-19 to be continued without modification.
Study and data analysis to be completed in the third quarter of 2021.
Immuron Limited
Studies done by Monash University Scientists at the Biomedicine Discovery Institute found that the SARS-CoV-2 inhibitory activity of IMM-124E is novel. This follows preliminary findings showing IMM-124E's neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.
The research team plans to identify the inhibitory molecule/s in IMM-124E.
CP-COV03 for the treatment of Covid-19
Presented positve results from the invivo study of CP-COV03, repurposed Niclosamide, at the 20th Science Council of Asia (SCA) Conference held in Guangzhou, China.
Hyundai Bioscience
Algernon Pharmaceuticals Inc.
Postive results were reported from the Phase 2b/3 Covid-19 trial showing reduced interleukin 6 (IL-6).
Cerecor Inc.
The FDA granted Fast Track designation to CERC-002 to treat hospitalized patients with COVID-19.
Trevena, Inc.
TRV027 has been selected for an National Institutes of Health (NIH)-funded ACTIV (Accelerating Covid-19 Therapeutic Interventions and Vaccines) trial in Covid-19 patients.
Vanderbilt University Medical Center (VUMC)
Positive data reported from the home cohort of SG016 Phase 2 study of SNG001 in Covid-19 patients. Also announced encouraging combined data for whole SG016 trial.
Data readout from the ongoing Phase 3 study in the second half of 2021.
Bavarian Nordic A/S
Additional preclinical data showing the vaccine candidate's ability to induce neutralizing antibodies against SARS-CoV-2 variants, were reported.
Phase 2 study to start in the second quarter of 2021.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
European Medicines Agency or EMA announced that Comirnaty, the COVID-19 vaccine developed by Pfizer and BioNTech, can have more flexible storage conditions, including up to one month in a normal fridge. The proposed change in the approved storage conditions, recommended by EMA's human medicines committee or CHMP, will help in easy handling of the vaccine in vaccination centres across the EU. Kraft Heinz Foods Co. is recalling around 13,504 pounds of a frozen foodservice soup product citing misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The frozen soup product contains milk and eggs, known allergens, which are not declared on the product label. Walmart has dropped the requirement of masks for customers and members who are fully vaccinated against COVID-19 while they are at the store. This is based on the latest guidance issued by the Centers for Disease Control and Prevention late last week. The retail giant also announced a cash bonus for all fully vaccinated associates.